Transarterial embolization with N-butyl 2-cyanoacrylate for the treatment of arterioportal shunts in patients with hepatocellular carcinoma

• Published in: Journal of cancer research and therapeutics Vol. 13; no. 4; p. 631
• Main Authors: Duan, Feng, Bai, Yanhua, Cui, Li, Li, Xiaohui, Yan, Jieyu, Zhu, Haiyan
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.01.2017; Medknow Publications & Media Pvt. Ltd
• Subjects: Abdomen; Adult; Aged; Biomarkers; Blood; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Care and treatment; Chemoembolization, Therapeutic - adverse effects; Chemoembolization, Therapeutic - methods; Enbucrilate - administration & dosage; Female; Hepatic Artery - drug effects; Hepatic Artery - pathology; Hepatocellular carcinoma; Humans; Laboratories; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Male; Medical imaging; Medical prognosis; Metastasis; Methods; Middle Aged; NMR; Nuclear magnetic resonance; Patients; Survival Rate; Therapeutic chemoembolization; Treatment Outcome; Veins & arteries; China; France
• ISSN: 0973-1482; 1998-4138; 1998-4138
• DOI: 10.4103/jcrt.JCRT_286_17

The aim of this study is to evaluate efficacy and safety of transarterial chemoembolization (TACE) with N-butyl 2-cyanoacrylate (NBCA) for the treatment of hepatocellular carcinoma (HCC) with arterioportal shunts (APS). From January 2008 to June 2014, 36 cases of HCC with APS were treated by TACE with NBCA. NBCA-lipiodol mixture was superselective delivered before routine TACE in HCC patients with APS. Recanalization of shunt, objective response, clinical adverse events, and survival rates was retrospectively studied. All interventional procedures were successful without any procedure relevant complications. The immediate APS improvement rate was 83.3% (30/36), and the APS improvement rate at first-time follow-up was 66.6% (20/30). Radiologically confirmed complete response (CR), partial response, stable disease, and progressive disease at 1 month after first chemoembolization were observed in 1 (2.7%), 19 (52.8%), 6 (16.7%), and 10 (27.8%) patients, respectively. Survival rates were 91.7% at 6 months, 47.2% at 1 year, and 13.9% at 2 years. The median survival time was 11 months. No severe adverse effects were noted. The preliminary experience indicates TACE with NBCA can be safely performed and may improve prognosis of HCC with arterioportal shunt.